The Claim
In adults with heterozygous familial hypercholesterolemia (HeFH) who are already on statin therapy, administering 20 mg of oral enlicitide daily for 24 weeks results in a mean reduction of 52.3% in non–high-density lipoprotein cholesterol (non–HDL-C), compared to a 2.1% change with placebo, yielding a between-group difference of −53.0% (95% CI: −58.5% to −47.4%, p < 0.001), demonstrating lipid-lowering effects on atherogenic lipids beyond LDL-C alone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with a genetic cholesterol problem and already taking statins, adding a pill called enlicitide every day for 6 months slashed bad cholesterol levels by over half, while a fake pill barely changed anything.
See the scientific wording
In adults with heterozygous familial hypercholesterolemia (HeFH) on statin therapy, 20 mg daily oral enlicitide for 24 weeks reduces non–high-density lipoprotein cholesterol (non–HDL-C) by a mean of 52.3% compared to a 2.1% change with placebo (between-group difference: −53.0%, 95% CI: −58.5% to −47.4%, p < 0.001), indicating broad atherogenic lipid-lowering effects beyond LDL-C alone.
What the research says
1 studyThe study tested the same pill, in the same people, for a similar time, and found exactly the cholesterol drop claimed. It shows the drug works as described.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.